Cutaneous Leishmaniases Clinical Trial
Official title:
Multicentric Non-Interventional Trial Evaluating Painless Hand Hygiene and LeiProtect® Dressing to Treat Complex Cutaneous Leishmaniasis in Algeria - LeiClean
This study evaluates the effect of clean wound management and dressing on complex zoonotic cutaneous leishmaniasis caused by L. major in the MENA region (Algeria). The patients will participate in the wound dressing themselves. The objective is to determine the amount of patients that can avoid systemic chemotherapy with pentavalent antimony which is compulsory for patients with complex CL lesions. In Algeria, this requires expensive hospital care because of the eventual toxic side effects of Sb(V).
The investigator initiated, non-interventional LeiClean Trial with 100 CL patients presenting
complex CL lesions, normally in need of a systemic an in-door treatment with meglumine
antimoniate and in risk of systemic antimony toxicity (see inclusion criteria!) during the CL
season of 2017/18 is part of the renewed cooperation treaty between the IPA and WM e. V. and
originates from encouraging compassionate use observations after topical LeiClean treatment
authorized by the Algerian Ministry of Health in December 2015. The study will be carried out
in the ZCL region of M'Sila and Bou Saada.
The German Regulation Authority, BfArM, has granted a special approval according to §11 MPG
(German regulation for Medical Devices) to the new filmogenic gel dressing LeiProtect®. The
patients with complex cutaneous leishmaniasis (Giemsa and PCR confirmed) elected for indoor
treatment with systemic antimony treatment are given the option for a LeiClean treatment of
their lesions; they are instructed on hand hygiene and LeiProtect® dressing of their lesions
which they carry out themselves at home during seven days. On day eight they come for lesion
cleansing and photographic monitoring before they start another weekly LeiClean cycle. The
patients can at any time opt for a conventional systemic chemotherapeutic treatment in a
hospital if they are not satisfied with their healing progress. However, if the doctor
realizes that after two months the hygienic wound management results in inadequate healing,
he can also order hospital for the patients. The doctor will allow the patients to visualise
their healing progress over the course of the trial through digital images on the computer.
After complete epithelisation of the lesions, the patients come for controls at monthly
intervals up to a period of five months to check for eventual lesion relapses. The costs of
the LeiClean outdoor treatment will be evaluated and compared to the already known hospital
costs per patient for a three-week systemic indoor Sb(V) treatment.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03208543 -
Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan
|
Phase 3 | |
| Completed |
NCT04512742 -
A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies
|
N/A | |
| Completed |
NCT04004754 -
Outcomes of Complicated CL in Ethiopia Treated With Miltefosine
|
||
| Active, not recruiting |
NCT05332093 -
Spatial Analysis of Host-parasite Interactions in Cutaneous Leishmaniasis in Ethiopia
|
||
| Active, not recruiting |
NCT04515186 -
Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World
|
Phase 3 | |
| Completed |
NCT02919605 -
Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis
|
Phase 2 | |
| Completed |
NCT03837431 -
Cutaneous Leishmaniasis Diagnostic Study
|
||
| Not yet recruiting |
NCT05493059 -
Study of Cases of Cutaneous Leishmaniasis Treated With Miltefosine in French Guiana, Retrospective Study
|
||
| Terminated |
NCT04001335 -
Diagnosis of Cutaneous Leishmaniasis Using the CL-detect Rapid Test in Travelers and Migrants in Belgium
|
||
| Completed |
NCT03929016 -
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03435419 -
Evaluation of Point-of-care Tests for the Diagnosis of Cutaneous Leishmaniasis in Afghanistan
|
N/A |